(VIANEWS) – The Market ended the session with GENEURO (GNRO.PA) rising 28% to €1.44 on Friday, following the last session’s upward trend. CAC 40 fell 0.4% to €7,420.69, following the last session’s upward trend on what was a somewhat down trend exchanging session today.
GENEURO’s last close was €1.13, 67.67% under its 52-week high of €3.48.
About GENEURO
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family; treats type 1 diabetes; and treats chronic inflammatory demyelinating polyneuropathy. It also developing GNK301. In addition, It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic centers to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.
Earnings Per Share
As for profitability, GENEURO has a trailing twelve months EPS of €-0.54.
Volume
Today’s last reported volume for GENEURO is 67070 which is 496.39% above its average volume of 11246.
More news about GENEURO (GNRO.PA).
